Q-omics provides the consensus-scored CRYZL2P profile across patient tissues and cancer cell-line models. CRYZL2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRYZL2P is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CRYZL2P RNA expression shows 19,505 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where CRYZL2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYZL2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYZL2P survival associations across molecular data types. CRYZL2P RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYZL2P RNA expression–survival associations across cancer types. High CRYZL2P expression shows unfavorable associations in LGG, UVM, BLCA and ESCA, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRYZL2P RNA expression.
This table summarizes CRYZL2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CRYZL2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYZL2P shows lower tumor expression in KICH, KIRP, LUSC and BRCA and higher tumor expression in STAD and LIHC. The KICH box plot shows higher CRYZL2P RNA expression in normal versus tumor tissue (log2 FC = −1.990, t-test p < 0.001).
This table shows molecular features associated with CRYZL2P in patient tissues and cancer cell lines. In patient samples, CRYZL2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
